Volume | 19,408 |
|
|||||
News | - | ||||||
Day High | 2.13 | Low High |
|||||
Day Low | 1.88 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Bio Path Holdings Inc | BPTH | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
2.09 | 1.88 | 2.13 | 1.91 | 2.03 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
141 | 19,408 | $ 2.02 | $ 39,139 | - | 1.88 - 44.80 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
18:57:01 | 40 | $ 1.89 | USD |
Bio Path Holdings Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.28M | 678.80k | - | 0 | -16.08M | -23.69 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Bio Path News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BPTH Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 2.17 | 2.38 | 1.88 | 2.05 | 68,100 | -0.21 | -9.68% |
1 Month | 2.84 | 3.0199 | 1.88 | 2.58 | 98,637 | -0.88 | -30.99% |
3 Months | 6.32 | 7.6699 | 1.88 | 4.14 | 1,565,400 | -4.36 | -68.99% |
6 Months | 9.45 | 12.366 | 1.88 | 4.51 | 788,942 | -7.49 | -79.26% |
1 Year | 33.60 | 44.80 | 1.88 | 10.55 | 1,159,467 | -31.64 | -94.17% |
3 Years | 114.20 | 172.398 | 1.88 | 39.05 | 525,029 | -112.24 | -98.28% |
5 Years | 291.00 | 486.80 | 1.88 | 91.41 | 526,370 | -289.04 | -99.33% |
Bio Path Description
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's lead drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. Its other drugs are BP1002 and BP1003. |